INSIGHTS ON CLINICAL TRIAL PARTNERING

• The Founder Behind The Platform

  Learn about the founding and mission of ClinAI, a groundbreaking platform that leverages automation and analytics to enhance vendor selection and management.

• Site Engagement Doesn't Start At First Patient In

  Site engagement starts long before enrollment. Explore how well-designed investigator meetings can set the tone, build trust, and give site teams the momentum they need to deliver.

• Paperless Online Remote Source Document Verification

  Learn how Clinical Trial Organizations, Monitoring Teams and Clinical Sites can benefit from the way Judi transforms rSDV from a logistical hurdle into a strategic asset.

• Clinical Trials In The Age Of Cost Caps

  On February 7, 2025, the NIH introduced a pivotal policy (NOT-OD-25-068), capping indirect cost recovery at 15% for research grants.

• PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

  7/29/2025

  Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

• Fast-Track Innovation, Address CMC Challenges In Expedited Pathways

  1/26/2026

  Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

• Flipping The Drug Development Industry On Its Head

  6/18/2024

  The video dives into the obstacles of the traditional outsourcing relationship between CROs and sponsors, and how Altasciences has broken from tradition to offer an alternative model.

• Use Case: A Patient-Centric Approach To Site Selection

  1/27/2025

  Discover how Citeline’s robust datasets, combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease. 

• Australia's Edge In Oncology And Nuclear Medicine Trials

  11/21/2025

  Discover how we leverage Australia’s world-class clinical infrastructure, streamlined regulatory environment, and early-phase expertise to accelerate oncology and nuclear medicine trials.